While the monoclonal antibody (mAb) targeting PD‐1 or PD‐L1 demonstrates effectiveness in treating NSCLC [159], not all patients with PD‐1/PD‐L1 positivity experience its benefits. This evidence concerns the gene CD274 and non-small cell lung carcinoma.